Novartis AG

Merck & Co. could have an edge in the cholesterol market with the first oral PCSK9 inhibitor. The company announced positive topline data on June 9 from the first two Phase III trials testing enli

For the third time, the US Federal Trade Commission has sent warning letters to drug companies, disputing improperly listed patents in the US Food and Drug Administration’s Orange Book. The agency tar

Otsuka’s release of supplemental Phase III data on June 6 for sibeprenlimab was the second major data readout in immunoglobulin A nephropathy (IgAN) of the week, following Vera’s Phase III data on Jun

The Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai